Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest Hodgkin lymphoma Stories

2014-02-04 08:34:21

Team Stephen vs. Hodgkin Lymphoma wants you to come to Paninis in Westlake from 2:00 - 4:00 on Sunday March 16th. ROCKY RIVER, Ohio, Feb. 4, 2014 /PRNewswire/ -- A Fundraising event co-sponsored by Budweiser and 5 Canadian Geese consulting, is planned for Sunday, March 16(th) at Paninis Bar & Grille on Detroit Road in Westlake. From 2:00 - 4:00 p.m., participants will experience Music and Entertainment provided by DJ Johnny, and enjoy unlimited Pizza, Pasta, and Pretzel Bites....

2013-12-18 11:12:18

Men with Hodgkin lymphoma who want to become fathers after their cancer treatment have greatly increased chances of doing so if they have frozen and stored semen samples beforehand, according to research published online today (Wednesday) in Europe's leading reproductive medicine journal Human Reproduction. In the first study to investigate the impact on fatherhood of freezing semen prior to cancer treatment, researchers questioned 902 male survivors of Hodgkin lymphoma in five European...

2013-09-16 08:30:16

WHITE PLAINS, N.Y. and HEIDELBERG, Germany, Sept. 16, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Affimed Therapeutics AG today announced a partnership to co-fund a phase 2 trial with the Recruit-TandAb AFM13, a novel tetravalent bispecific antibody directed against human CD30 and CD16A in Hodgkin lymphoma (HL) patients for whom currently available treatments have failed . AFM13 is a first-in-class immunotherapy drug designed to treat HL patients and patients...

2012-06-27 22:41:33

A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options. Loyola University Medical Center oncologist Scott E. Smith, MD, PhD presented survival data for the drug, brentuximab vedotin (Adcetris®), at the 17th Congress of the European Hematology Association. Smith is director of Loyola's Hematological Malignancies Research Program. The multi-center study included 102...

2012-06-27 14:19:38

Trial led by St. Jude Children's Research Hospital investigators succeeds in keeping cure rates high for young patients with favorable-risk Hodgkin lymphoma while reducing their chances of serious treatment side effects A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second cancers, infertility, heart and other problems later. St....

2012-06-26 10:24:25

Trial led by St. Jude Children's Research Hospital investigators succeeds in keeping cure rates high for young patients with favorable-risk Hodgkin lymphoma while reducing their chances of serious treatment side effects MEMPHIS, Tenn., June 26, 2012 /PRNewswire-USNewswire/ -- A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second...

2011-12-13 07:00:00

QUÓ°BEC CITY, Dec. 13, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today reported encouraging clinical data for an ongoing Phase 2 clinical study in patients with refractory/relapsed Hodgkin Lymphoma. Preliminary response data showed that perifosine combined with sorafenib significantly increased median progression free survival (PFS) in refractory/relapsed Hodgkin Lymphoma patients with high phosphorylation levels of...

2011-12-12 07:00:00

QUÓ°BEC CITY, Dec. 12, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today reported encouraging preclinical data for its oral anticancer Akt inhibitor, perifosine, in Hodgkin Lymphoma. In vitro data from Hodgkin lymphoma (HL) cell lines showed that perifosine combined with sorafenib induced increased apoptosis, while in vivo data for the same combination treatment for HL significantly increased survival in mice. Data...

2011-08-19 16:10:00

WHITE PLAINS, N.Y., Aug. 19, 2011 /PRNewswire/ -- Today the Food and Drug Administration (FDA) approved Seattle Genetics' Adcetris to treat two types of rare blood cancers - Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). (Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO ) The drug is approved for Hodgkin lymphoma patients after failure of a stem cell transplant or two chemotherapy treatments and for ALCL patients after failure of at least one multi-agent...

2011-08-19 13:52:00

SILVER SPRING, Md., Aug. 19, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Lymphomas are cancers of the lymphatic system. Adcetris is an antibody-drug conjugate that combines an antibody and drug, allowing the antibody to direct the drug to a target on...